


MATERIALITY MATRIX



Materiality is used to identify which social and environmental issues are of greatest interest to both a business and its stakeholders.

In 2016 AbbVie’s Corporate Responsibility team conducted an update to our Materiality Matrix to ensure it reflects the most material issues for AbbVie today. We collected and assessed data from a range of internal and external sources to identify and map material issues. We conducted materiality interviews with a broad cross-section of external stakeholders including global health experts, non-profit organizations, patient groups, academics, suppliers, and industry associations. In addition, insights gathered during interviews with executives and leaders across the business, along with key business document review, also contributed to identifying material issues. Ultimately 25 issues most material for AbbVie today are mapped in the resulting matrix.

We will continue to build on progress made against these issues. As part of our patient-first approach, we work in close partnership with our stakeholders to increase access and improve patient treatment outcomes. For additional information about our commitment and patient support initiatives, see <http://www.abbvie.com/responsibility/transparency-policies/home.html> and <http://www.abbvie.com/responsibility/improve-health-outcomes/patient-support.html>. Additionally, we continue to advance our pipeline in both small molecules and biologics – tackling diseases where there is significant patient need for access to more and better solutions. For additional information about pipeline, see <http://www.abbvie.com/research-innovation/pipeline.html>.